MIRA Pharmaceuticals, an early-stage biopharma focused on novel neurological and inflammatory conditions, announced positive unblinded results from its Phase 1 clinical trial of Ketamir-2, a selective oral NMDA receptor modulator. The successful safety and pharmacokinetic profile support advancing to a Phase 2a study targeting chemotherapy-induced peripheral neuropathy (CIPN) planned for Q2 2026. Despite this clinical progress, MIRA remains pre-revenue with no approved products and continues to rely heavily on external funding to sustain operations. The company faces typical early-stage biotech risks including regulatory uncertainty, lack of patent protection on some candidates, and operational dependency on third parties for manufacturing and trials. Capital availability and successful execution of the clinical programs will determine its medium-term viability.